Cryoport Earnings Call Transcripts
Fiscal Year 2026
-
Q2 2026 saw $49M in revenue, 15% growth in Life Sciences Services, and positive Adjusted EBITDA. Guidance for 2026 is reaffirmed at $192M-$196M, with strong demand, new product launches, and operational milestones supporting sustainable growth.
-
The meeting covered director elections, auditor ratification, executive compensation, and an equity plan amendment. All proposals passed, with official results to be filed in a Form 8-K within four business days.
-
Q1 2026 revenue grew 16% year-over-year to $47.8M, with strong double-digit gains across both Life Sciences Services and Products. Full-year guidance was raised to $192–$196M, and positive adjusted EBITDA is expected in the second half, driven by robust demand and operational improvements.
Fiscal Year 2025
-
Full year 2025 revenue reached $176.2M, exceeding guidance, with strong growth in commercial cell and gene therapy and life sciences services. 2026 guidance is $190–$194M, with positive adjusted EBITDA expected in H2 2026.
-
Double-digit revenue growth continued in both core segments, with commercial cell and gene therapy revenue up 36% year-over-year. Updated 2025 revenue guidance to $170–$174 million, targeting positive adjusted EBITDA by year-end, and significant operating leverage expected in 2026–2027.
-
Double-digit revenue growth in Q2 2025 was driven by strong gains in Life Sciences Services and Products, improved margins, and a transformative partnership with DHL. Guidance for 2025 is reaffirmed, with a robust balance sheet and continued leadership in cell and gene therapy supply chain solutions.
-
Q1 revenue grew 10% year-over-year to $41M, led by 17% growth in life sciences services and 33% growth in commercial cell and gene therapy revenue. Strategic partnership with DHL and the sale of CryoPDP for $195M will strengthen global reach and financials. FY25 revenue guidance is $165M–$172M.
-
A strategic partnership with DHL, including the sale of CRYOPDP for $195 million, will accelerate growth, enhance global reach, and improve margins, with 2025 revenue guidance set at $165–$173 million. The move sharpens focus on cell and gene therapy and strengthens financial flexibility.
Fiscal Year 2024
-
2024 revenue reached $228.4M, with strong growth in life sciences services and commercial cell and gene therapy. Gross margin improved to 45.8% in Q4, and 2025 guidance is $240–$250M with a return to positive adjusted EBITDA expected.
-
Life Sciences Services and BioStorage drove Q3 growth, offsetting continued softness in products. Cost reduction and realignment improved margins and cash flow, with positive adjusted EBITDA targeted for 2025. Full-year revenue guidance of $225M–$235M was reaffirmed.
-
Sequential revenue growth was driven by strong cell and gene therapy demand, while MVE products faced continued softness due to excess capacity and delayed spending. Cost reduction initiatives are on track to deliver $22 million in annualized savings, supporting a return to positive Adjusted EBITDA in 2025.